Boehringer Ingelheim announces European Medicines Agency’s filing acceptance and validation of marketing authorization application for spesolimab in generalized pustular psoriasis
The marketing authorization application (MAA) package includes results from the pivotal Effisayil-1 global trial
INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim announced today that the company’s marketing authorization application (MAA) for the treatment of flares in generalized pustular psoriasis (GPP), has been validated and is now under evaluation with the European Medicines Agency (EMA).
“GPP is a rare, life-threatening neutrophilic skin disease characterized by painful, sterile pus-filled blisters, that can suddenly appear over the body,” said Dr. Janine Lamar, Global Spesolimab Lead at Boehringer Ingelheim. “Despite its name, GPP is very different to the more common plaque psoriasis. With no approved treatments in the EU for GPP flares, acceptance of the application for review of spesolimab brings us one step closer to providing a targeted treatment for people with this distressing, unpredictable and painful skin condition.”
GPP is characterized by episodes of widespread eruptions of painful, sterile pustules (blisters of non-infectious pus).1,2,3 The inflammation can also affect other parts of the body and can lead to infections or other organ complications that may be life-threatening.
There is a high unmet need for treatments that can rapidly and completely resolve the symptoms of GPP flares. Flares greatly affect a person’s quality of life4 and can lead to hospitalization with life-threatening complications, such as heart failure, renal failure, sepsis and even death.5
The marketing authorization application was based on the 12 week Effisayil-1 trial; a multi-center, double-blind, randomized, placebo-controlled trial that evaluated efficacy, safety, and tolerability of spesolimab (single dose 900 mg spesolimab i.v., with the option of a 2nd dose if symptoms persisted on Day 8) in patients experiencing a GPP flare.6 The study demonstrated superiority over placebo in pustular clearance after one week of treatment.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/ema-filing-acceptance-and-validation-spesolimab
Tinubu(R) Square Americas Nam
全民斗舞一触即发,大型舞蹈竞技真人秀《舞斗
炎帝生物:炎帝陵祭祖大典暨公益助学活动盛大
Intelsat将为Japan Airlines提供2Ku
首届中国(沈阳)国际生物医药产业高质量发展
柯淋尼立志打造不锈钢全屋定制领军品牌,引领
National Football League
Zynga与Alec Baldwin预告创意合作
Kanguru推出独立于操作系统的新型加密指
NTT推出可扩展的云原生托管检测与响应安全服务
短视频电商怎么做?点进来看干货!
Mytheresa宣布完成首次公开发行及承销商全面行使
Theramex推出新网站
新研究发现,无创连续血红蛋白监测可改善患儿
Octapharma将在ISTH 2019上呈报血友病
玫琳凯公布2022全年奖项、里程碑和成就
借助AMPLI项目,塑性转化模拟将把增强现实提升
Mavenir被以色列Partner选为下一代网络
Bitgate Selects BitGo for Its
游客青睐中国最大盐湖——察尔汗盐湖
史密斯探测公司为横滨海关提供货物检查系统
沃特世推出灵敏度出众的紧凑型台式串联四极杆
电商法来了!“刷好评”“删差评”按违法论处
禾晨信用评级授予廷镁服饰AAA信用企业